newsfilter
← Earnings
Earnings Releases·

Jasper Therapeutics — Third Quarter 2026 Earnings Summary

  • Revenue reached $8.0 million for the quarter ended September 30, 2026, compared to $0 in the prior year period, while net loss widened to $144.5 million from $18.7 million, driven largely by a $129.5 million in-process R&D charge from the Kira Pharmaceuticals acquisition.
  • Cash and cash equivalents increased to $135.3 million as of September 30, 2026, following a $132.0 million private placement of non-voting convertible preferred stock and the July 2026 all-stock acquisition of Kira Pharmaceuticals.
  • Clinical progress includes the completion of the first cohort enrollment in the Phase 2 renal basket study for IgAN, the commencement of enrollment in the C3G/IC-MPGN cohort, and the opening of an expansion cohort for FSGS.
  • Future data milestones are projected for the fourth quarter of 2026, including interim IgAN data and initial Phase 1/2 results for briquilimab in SCID, with updated renal basket data and the first FSGS patient dosing expected in the first quarter of 2027.
  • The company completed a 1-for-30 reverse stock split in November 2026 and reduced outstanding warrants by tendering 283,689 warrants for approximately $2.8 million, leaving 127,834 warrants outstanding.
Company
JASPER THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology